Francesca Palandri

机构：IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Istituto di Ematologia di Bologna, University of Bologna · ORCID：0000-0001-8367-5668

发表论文 570 篇 · 总被引 10078 次 · h-index 53

代表论文

• Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis (2026 · Blood · 被引 10)
• JAK inhibitor selection in challenging scenarios of myelofibrosis: a review (2025 · Haematologica · 被引 8)
• Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study (2026 · Cancer · 被引 4)
• Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia (2026 · Blood Advances · 被引 4)
• POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib (2026 · Future Oncology · 被引 3)
• Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor–Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1 (2026 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)